The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients
Abstract
FTY720 is a novel immunomodulator to be developed for use in organ transplantation. The primary objective of this study was to measure safety, single-dose pharmacokinetics, and pharmacodynamics in stable renal transplant patients-the first human use of FTY720. This study used a randomized, double-blind, placebo-controlled design that explored single oral doses of FTY720 from 0.25 to 3.5 mg in 20 stable renal transplant patients on a cyclosporine-based regimen. Safety assessments and blood samples were taken predose and at multiple time points during a 96-h period postdose. Standard pharmacokinetic parameters were derived from the FTY720 whole blood concentrations, measured by HPLC/MS/MS. FTY720 was well tolerated, with no serious adverse events. Transient, asymptomatic bradycardia occurred after administration in 10 of 24 doses of FTY720. Pharmacokinetics are characterized by a prolonged absorption phase; the terminal elimination phase started 36 h after the administration, with elimination half-life (t(1/2)) ranging from 89 to 157 h independent of dose. Maximum plasma concentration and AUC were proportional to dose with low intersubject variability, the apparent volume of distribution (V(d)/F) ranged from 1116 to 1737 L. FTY pharmacodynamics were characterized by a reversible transient lymphopenia within 6 h, the nadir being 42% of baseline. The lymphocyte count returned to baseline within 72 h in all dosing cohorts except the highest. Single oral doses of FTY720 ranging from 0.25 to 3.5 mg were well tolerated and caused a reversible selective lymphopenia. Transient, but asymptomatic bradycardia was the most common adverse event. The long t(1/2) suggests less frequent dosing intervals. The size of V(d)/F is in excess of blood volume, consistent with widespread tissue distribution
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., & Hoshino, Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.5037 · Cited by 596
Sphingolipids in Food and the Emerging Importance of Sphingolipids to Nutrition
Vesper, H., Schmelz, E.-M., Nikolova-Karakashian, M. N., Dillehay, D. L., Lynch, D. V., & Merrill, A. H. (1999) · The Journal of Nutrition · doi:10.1093/jn/129.7.1239 · Cited by 582
FUJITA, T., INOUE, K., YAMAMOTO, S., IKUMOTO, T., SASAKI, S., TOYAMA, R., CHIBA, K., HOSHINO, Y., & OKUMOTO, T. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.208 · Cited by 540
Pinschewer, D. D., Ochsenbein, A. F., Odermatt, B., Brinkmann, V., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5761 · Cited by 365
Adachi, K., Kohara, T., Nakao, N., Arita, M., Chiba, K., Mishina, T., Sasaki, S., & Fujita, T. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00127-f · Cited by 304
Suzuki, S., Enosawa, S., Kakefuda, T., Shinomiya, T., Amari, M., Naoe, S., Hoshino, Y., & Chiba, K. (1996) · Transplantation · doi:10.1097/00007890-199601270-00006 · Cited by 283
Yanagawa, Y., Sugahara, K., Kataoka, H., Kawaguchi, T., Masubuchi, Y., & Chiba, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5493 · Cited by 260
Uptake and Metabolism of Sphingolipids in Isolated Intestinal Loops of Mice
Schmelz, E.-M., Crall, K. J., Larocque, R., Dillehay, D. L., & Merrill, A. H. (1994) · The Journal of Nutrition · doi:10.1093/jn/124.5.702 · Cited by 199
FTY720: ALTERED LYMPHOCYTE TRAFFIC RESULTS IN ALLOGRAFT PROTECTION
Brinkmann, V., Pinschewer, D. D., Feng, L., & Chen, S. (2001) · Transplantation · doi:10.1097/00007890-200109150-00002 · Cited by 169
Chiba, K., Hoshino, Y., Suzuki, T., Masubuchi, Y., Yanagawa, Y., Ohtsuki, M., Sasaki, S., & Fujita, T. (1996) · PubMed · Cited by 127
Cited by
Immunosuppressive Drugs for Kidney Transplantation
Halloran, P. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra033540 · Cited by 1,555
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Self-citation“Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
Takabe, K., Paugh, S. W., Milstien, S., & Spiegel, S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07113 · Cited by 718
The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors
Gräler, M. H., & Goetzl, E. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-0910fje · Cited by 539
An update on the biology of sphingosine 1-phosphate receptors
Blaho, V. A., & Hla, T. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046300 · Cited by 516
Metadata
- Authors
- Budde, K., Schmouder, R. L., Brunkhorst, R., Nashan, B., Lu[Combining Diaeresis]cker, P. W., Mayer, T., Choudhury, S., Skerjanec, A., Kraus, G., & Neumayer, H. H.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2002-04
- Volume
- 13
- Issue
- 4
- Pages
- 1073-1083
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2165704853
- Cited by
- 270
- References
- 13
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients. https://app.cochat.ai/papers/10.1681/asn.v1341073
- The paper
- Budde, K., Schmouder, R. L., Brunkhorst, R., Nashan, B., Lu[Combining Diaeresis]cker, P. W., Mayer, T., Choudhury, S., Skerjanec, A., Kraus, G., & Neumayer, H. H. (2002). First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v1341073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.